This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
May 27, 2013 /PRNewswire/ --
Roll out in
Norway to follow shortly
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA
Sweden, the third and fourth European markets where the product is now available. Alcon will roll out the drug in
mid-March 2013, JETREA
® was approved by the European Commission (EC) for the treatment of vitreomacular traction (VMT), including when associated with a macular hole of diameter less than or equal to 400 microns.
Alcon's first European launch of JETREA
® took place in the UK last month, followed by
Germany earlier this month. Alcon, a division of Novartis, acquired the rights to commercialize JETREA
the United States in
Under the terms of this deal ThromboGenics has already received €165 million in upfront and milestone payments, including €90 million following EMA approval of JETREA
® and first injection (UK) in patients. The company could receive a further €210 million in milestones plus significant royalties on Alcon's sales of JETREA
ThromboGenics launched JETREA
® in the US in
mid-January 2013 where it is approved for the treatment of patients with symptomatic vitreomacular adhesion (VMA). US sales since launch are in line with the Company's expectations.
Dr Patrik De Haes, CEO of ThromboGenics, says:"We are extremely encouraged by our partner Alcon's rapid progress in making JETREA®available acrossEurope. We look forward to further launches across the Nordic region and other countries to ensure that patients are able to have access to the first pharmacological treatment for VMT including when associated with a macular hole of diameter less than or equal to 400 microns."
® contains the active substance ocriplasmin. It is administered through a single intravitreal injection to treat adults with vitreomacular traction (VMT).
VMT, which in the US is referred to as symptomatic VMA, is an age-related progressive, sight-threatening condition. It is caused by the vitreous humour having an abnormally strong attachment to the macula, the central part of the retina (the light sensitive membrane at the back of the eye). The macula provides central vision that is needed for everyday tasks such as driving, reading and recognizing faces.